Table 1
| SWOG/ Support |
STUDY | R E G |
O P E N |
ARM | ACCR. GOAL |
TOTAL REGS. |
REGS. LAST 12 Month |
REGS. LAST 6 Month |
REGS. LAST 3 Month |
REGS. LAST 30 DAYS |
REGS. LAST 7 DAYS |
DATE OF FIRST REG. |
# of ACT. INSTs |
# of CURR IRBs |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SWOG | S1320-Adv, BRAF mut, Inter v Contin | 1 | Y | 1 Lead-in Continuous Dosing | 280 | 171 | 59 | 34 | 14 | 5 | 1 | 09/19/2014 | 246 | 110 |
| 171 | 59 | 34 | 14 | 5 | 1 | |||||||||
| 2 | Y | 2 Continuous Dosing | 280 | 70 | 23 | 16 | 7 | 2 | 1 | 09/19/2014 | ||||
| 3 Intermittent Dosing | 70 | 25 | 11 | 6 | 4 | 2 | ||||||||
| 140 | 48 | 27 | 13 | 6 | 3 | |||||||||
| S1404-Melan, Adv, HD-IFN/Ipilimumab vs MK-3475 | 1 | N | 1 Tissue for PD-L1 testing | 1378 | 1426 | 992 | 470 | 213 | 0 | 0 | 11/10/2015 | 392 | 172 | |
| 1426 | 992 | 470 | 213 | 0 | 0 | |||||||||
| 2 | Y | 2 FDA approved regimen | 1378 | 678 | 488 | 243 | 118 | 21 | 1 | 11/10/2015 | ||||
| 3 MK-3475 (Pembrolizumab) | 667 | 484 | 243 | 110 | 20 | 0 | ||||||||
| 1345 | 972 | 486 | 228 | 41 | 1 | |||||||||
| S1512-Melan, Adv, Desmoplastic, MK-3475 (pembro) | 1 | Y | 1 MK-3475 (pembrolizumab) | 77 | 3 | 3 | 2 | 2 | 0 | 0 | 02/06/2017 | 73 | 31 | |
| 3 | 3 | 2 | 2 | 0 | 0 | |||||||||
| Yes | EA6134-Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T | 1 | E | Total Registrations | 19 | 12 | 4 | 3 | 2 | 2 | 11/03/2015 | 336 | 143 | |
| 19 | 12 | 4 | 3 | 2 | 2 | |||||||||
| 2 | E | Total Registrations | 5 | 4 | 2 | 2 | 1 | 0 | 11/03/2015 | |||||
| 5 | 4 | 2 | 2 | 1 | 0 | |||||||||
| EA6141-Melan, Avd, Nivolumab+Ipi ± Sargmostim | 1 | E | Total Registrations | 36 | 27 | 18 | 4 | 0 | 0 | 03/25/2016 | 299 | 123 | ||
| 36 | 27 | 18 | 4 | 0 | 0 | |||||||||
| No | E3612-MELAN,Adv Ipilimumab±Bevacizumab | 1 | E | Total Registrations | 6 | 2 | 1 | 1 | 1 | 0 | 02/16/2015 | 138 | 50 | |
| 6 | 2 | 1 | 1 | 1 | 0 | |||||||||